Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Breast Neoplasms × belzutifan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 5 von Hippel-Lindau Disease 2 Pheochromocytoma 2 Paraganglioma 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Ovarian Neoplasms 1 Neuroectodermal Tumors, Primitive 1 Neoplasm Metastasis 1 Metastatic Castration-Resistant Prostate Cancer 1 Kidney Neoplasms 1 Hemangioblastoma 1 Endometrial Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma 1 Breast Neoplasms 1 Adenoma, Islet Cell 1

Interventions

Fulvestrant 50 Trastuzumab 40 Letrozole 40 pembrolizumab 39 Capecitabine 39 ribociclib 35 abemaciclib 33 Paclitaxel 31 Cyclophosphamide 31 Carboplatin 31 Specimen Handling 29 Blood Specimen Collection 28 trastuzumab deruxtecan 27 pertuzumab 25 Surveys and Questionnaires 25 Docetaxel 23 Magnetic Resonance Spectroscopy 21 Anastrozole 21 Tamoxifen 20 Biopsy 20 palbociclib 19 Radiotherapy 18 130-nm albumin-bound paclitaxel 18 sacituzumab govitecan 17 exemestane 17 Injections 17 Neoadjuvant Therapy 16 olaparib 15 Exercise 15 eribulin 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06428396 2025-12-26

LITESPARK-029

Merck Sharp & Dohme LLC

Phase 2 Recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡